explore -WSS

explore

author：Wikipedia 2025-09-28 23:05:39 - browse：61

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Change Healthcare cyberattack prompts Medicare loan program

WSS

Just how do doctors, lawmakers, and the public define abortion?

The leaders of Italy and Poland say European Union should focus on stopping migration

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Israel withdraws forces after 2

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Alkermes shareholders re

Amylyx ALS drug fails large clinical trial

Anesthesiologist group: stop taking Ozempic before surgery

Pentagon will tighten controls on classified information after Discord leak

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

New air purifier tech could be key to improving indoor air quality

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

explore

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Headspace, Meta partner to launch VR meditation app for Quest

UnitedHealth quietly bought dozens of outpatient centers

What it’s like to watch children die of measles

Former medical device CEO who sold dummy, plastic parts convicted of fraud

UnitedHealth quietly bought dozens of outpatient centers

explore

knowledge

focus

entertainment